Insiders Trades

★ Sign in to follow

NS

Natarajan Sethuraman

CEO

President, Research & Develop.

US·SEC (Form 4)

Entrada Therapeutics, Inc.

Insider activity · 24 months0 buys4 salesCumulative net flow

Nov 24 · 0 buys · 3 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 1 saleJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

21

Company

1

▲ Purchases (0 ops.)

—

▼ Sales (10 ops.)

€538k

Latest filing published 03 Sept 2026 for Entrada Therapeutics, Inc., €13k.

Filing timeline

BuySale

Natarajan Sethuraman

Insider track record

Disclosed buys

0

Disclosed sells

10

Signal history

Natarajan Sethuraman: trading record in brief

All filings by Natarajan Sethuraman on record concern Entrada Therapeutics, Inc., in the capacity of chief executive. We count 21 filings; the first trade dates from 1 March 2022 and the latest from 2 September 2026.

No open-market purchase appears, only 10 sales worth €538k. Outside the open market, there are 11 share grants. 2026 to date brings no purchases and 1 sale.

Most recently, on 3 September 2026, the filings show a share grant worth €13k in Entrada Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Natarajan Sethuraman

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Entrada Therapeutics, Inc. (US)

Declarations21 total

◆

Natarajan Sethuraman

President, Research & Develop.Executives2 Sept 2026Entrada Therapeutics, Inc.

14,852 USD28SEC

2,079 shares@ US$7.14390.0058% mcap2.3% of flowCommon StockSEC:0001873394-26-000005:0

▼

Natarajan Sethuraman

President, Research & Develop.Executives4 May 2026Entrada Therapeutics, Inc.

398,810 USD28SEC

25,907 shares@ US$15.39390.14% mcap60.3% of flowCommon StockSEC:0001873394-26-000003:0

◆

Natarajan Sethuraman

President, Research & Develop.Executives1 Mar 2026Entrada Therapeutics, Inc.

0SEC

55,800 shares0Common StockSEC:0001873394-26-000001:0

◆

Natarajan Sethuraman

President, Research & Develop.Executives2 Sept 2025Entrada Therapeutics, Inc.

9,557 USD22SEC

1,760 shares@ US$5.43021.5% of flowCommon StockSEC:0001873394-25-000003:0

◆

Natarajan Sethuraman

President, Research & Develop.Executives1 Mar 2025Entrada Therapeutics, Inc.

0SEC

60,800 shares0Common StockSEC:0001689375-25-000012:0

▼

Natarajan Sethuraman

President, Research & Develop.Executives29 Nov 2024Entrada Therapeutics, Inc.

2,000 USD22SEC

100 shares@ US$20.000.3% of flowCommon StockSEC:0001689375-24-000067:0

▼

Natarajan Sethuraman

President, Research & Develop.Executives11 Nov 2024Entrada Therapeutics, Inc.

28,191 USD22SEC

1,409 shares@ US$20.00794.6% of flowCommon StockSEC:0001689375-24-000066:0

▼

Natarajan Sethuraman

President, Research & Develop.Executives4 Nov 2024Entrada Therapeutics, Inc.

13,498 USD22SEC

749 shares@ US$18.0222.2% of flowCommon StockSEC:0001689375-24-000064:0

▼

Natarajan Sethuraman

President, Research & Develop.Executives16 Oct 2024Entrada Therapeutics, Inc.

10,800 USD34SEC

600 shares@ US$18.001.8% of flowCommon StockSEC:0001689375-24-000057:0

▼

Natarajan Sethuraman

Chief Scientific OfficerExecutives6 Sept 2024Entrada Therapeutics, Inc.

9,141 USD26SEC

600 shares@ US$15.23561.5% of flowCommon StockSEC:0001689375-24-000053:0

◆

Natarajan Sethuraman

Chief Scientific OfficerExecutives3 Sept 2024Entrada Therapeutics, Inc.

7,392 USD11SEC

469 shares@ US$15.76111.2% of flowCommon StockSEC:0001689375-24-000050:0

▼

Natarajan Sethuraman

Chief Scientific OfficerExecutives12 Jul 2024Entrada Therapeutics, Inc.

10,800 USD26SEC

600 shares@ US$18.001.8% of flowCommon StockSEC:0001689375-24-000041:0

▼

Natarajan Sethuraman

Chief Scientific OfficerExecutives16 May 2024Entrada Therapeutics, Inc.

15,000 USD23SEC

1,000 shares@ US$15.002.4% of flowCommon StockSEC:0001689375-24-000031:0

◆

Natarajan Sethuraman

Chief Scientific OfficerExecutives1 Mar 2024Entrada Therapeutics, Inc.

0SEC

44,100 shares0Common StockSEC:0001689375-24-000003:0

◆

Natarajan Sethuraman

Chief Scientific OfficerExecutives1 Sept 2023Entrada Therapeutics, Inc.

0SEC

14,200 shares0Common StockSEC:0001689375-23-000063:0

▼

Natarajan Sethuraman

Chief Scientific OfficerExecutives10 Jul 2023Entrada Therapeutics, Inc.

54,474 USD24SEC

3,026 shares@ US$18.0028.7% of flowCommon StockSEC:0001689375-23-000046:0

▼

Natarajan Sethuraman

Chief Scientific OfficerExecutives17 Apr 2023Entrada Therapeutics, Inc.

71,316 USD24SEC

3,961 shares@ US$18.004511.5% of flowCommon StockSEC:0001689375-23-000031:0

◆

Natarajan Sethuraman

Chief Scientific OfficerExecutives1 Mar 2023Entrada Therapeutics, Inc.

0SEC

14,200 shares0Common StockSEC:0001689375-23-000029:0

◆

Natarajan Sethuraman

Chief Scientific OfficerExecutives1 Mar 2023Entrada Therapeutics, Inc.

0SEC

28,400 shares0Common StockSEC:0001689375-23-000014:0

◆

Natarajan Sethuraman

Chief Scientific OfficerExecutives1 Sept 2022Entrada Therapeutics, Inc.

0SEC

5,794 shares0Common StockSEC:0001104659-22-097876:0

◆

Natarajan Sethuraman

Chief Scientific OfficerExecutives1 Mar 2022Entrada Therapeutics, Inc.

0SEC

11,588 shares0Common StockSEC:0001104659-22-030008:0

21 of 21 declarations